BCTXW | BriaCell Therapeutics Corp. Annual & Quarterly

Annual Income Statements

(In USD)

Breakdown	2024	2023	2022	2021	2020	2019
Revenue	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expenses	33.33 Million	23.27 Million	-3388.00	-3.68 Million	-1.38 Million	-946.42 Thousand
Selling, General and Administrative Expenses	6.15 Million	7.93 Million	7.26 Million	-3.67 Million	-1.37 Million	-932.16 Thousand
Research and Development Expenses	27.17 Million	15.33 Million	8.02 Million	1.31 Million	2.22 Million	3.73 Million
Other Expenses	-	-	-	-	-58.97 Thousand	319.85 Thousand
Cost and Expenses	-	23.27 Million	-3388.00	-3.68 Million	-1.38 Million	-946.42 Thousand
Operating Income	-4.79 Million	-23.27 Million	-15.28 Million	-6.97 Million	-3.6 Million	-4.73 Million
Interest Expense	-	-	979.00	46.09 Thousand	26.99 Thousand	23.81 Thousand
Income Tax Expense	-	-152.62 Thousand	979.00	6.58 Million	-72.25 Thousand	343.74 Thousand
Earnings before Tax	-4.79 Million	-20.3 Million	-11.54 Million	3.68 Million	1.38 Million	946.42 Thousand
Net Income	-4.79 Million	-20.3 Million	-11.54 Million	3.68 Million	1.38 Million	946.42 Thousand
Earnings Per Share Basic	-0.29	-1.31	-	-	-	-
Earnings Per Share Diluted	-0.29	-1.31	-	-	-	-
Weighted Average Shares Outstanding	16.45 Million	15.51 Million	-	-	-	-
Weighted Average Shares Outstanding (Diluted)	16.45 Million	15.51 Million	-	-	-	-
Gross Margin	-	-	-	-	-	-
EBIT Margin	-	-	-	-	-	-
Profit Margin	-	-	-	-	-	-
EBITDA	-4.79 Million	-22.36 Million	-11.5 Million	3.7 Million	1.39 Million	960.67 Thousand
Earnings Before Tax Margin	-	-	-	-	-	-

Breakdown	2024 Q4	2024 Q3	2024 Q2	2024 Q1	2023 FY	2023 Q4
Revenue	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expenses	5.76 Million	9.22 Million	9.82 Million	8.5 Million	23.27 Million	7.7 Million
Selling, General and Administrative Expenses	1.36 Million	1.57 Million	1.57 Million	1.64 Million	-	2.53 Million
Research and Development Expenses	4.4 Million	7.65 Million	8.25 Million	6.85 Million	-	5.16 Million
Other Expenses	-	-	-	-	-	-
Cost and Expenses	5.76 Million	9.22 Million	9.82 Million	8.5 Million	23.27 Million	7.7 Million
Operating Income	-5.76 Million	-9.22 Million	-9.82 Million	-8.5 Million	-23.27 Million	-7.7 Million
Interest Expense	-	-	-	-	-	-
Income Tax Expense	24.04 Million	-10.98 Million	1.44 Million	-14.5 Million	-152.62 Thousand	-7.39 Million
Earnings before Tax	-1.24 Million	1.69 Million	-11.33 Million	5.95 Million	-20.3 Million	-2.41 Million
Net Income	-1.21 Million	1.71 Million	-11.29 Million	6 Million	-20.3 Million	-2.41 Million
Earnings Per Share Basic	-0.07	102.89	-0.71	0.90	-	-0.16
Earnings Per Share Diluted	-0.07	102.89	-0.71	0.87	-	-0.16
Weighted Average Shares Outstanding	16.45 Million	16.67 Million	15.98 Million	16.67 Million	15.51 Million	15.51 Million
Weighted Average Shares Outstanding (Diluted)	16.45 Million	16.67 Million	15.98 Million	16.67 Million	15.51 Million	15.51 Million
Gross Margin	-	-	-	-	-	-
EBIT Margin	-	-	-	-	-	-
Profit Margin	-	-	-	-	-	-
EBITDA	-5.69 Million	-20.16 Million	-8.25 Million	-22.77 Million	-	-7.49 Million
Earnings Before Tax Margin	-	-	-	-	-	-